Table III.
Event-free survival | Overall survival | |||
---|---|---|---|---|
Variable | HR (95% CI) | P-value | HR (95% CI) | P-value |
Age | ||||
<60 | 2.590 (0.624–10.745) | 0.190 | 2.119 (0.461–9.729) | 0.334 |
≥60 | ||||
Sex | ||||
Female | 0.650 (0.156–2.703) | 0.553 | 0.799 (0.174–3.671) | 0.773 |
Male | ||||
TNM stage | ||||
I | 5.521 (1.321–23.076) | 0.019a | 9.468 (2.052–43.679) | 0.004a |
II–IV | ||||
Tumor stage | ||||
T1-2 | 0.678 (0.259–1.777) | 0.429 | 0.512 (0.184–1.424) | 0.200 |
T3-4 | ||||
Nodal status | ||||
N0 | 1.450 (0.508–4.143) | 0.488 | 1.434 (0.482–4.269) | 0.517 |
N1 | ||||
Metastasis | ||||
M0 | 1.470 (0.723–2.986) | 0.287 | 1.198 (0.548–2.618) | 0.650 |
M1 | ||||
Nuclear grade | ||||
1–2 | 0.962 (0.668–1.385) | 0.834 | 0.924 (0.632–1.349) | 0.681 |
3–4 | ||||
RSF1 expression status | ||||
High | 0.176 (0.066–0.472) | 0.001a | 4.023 (1.263–12.820) | 0.019a |
Low |
P-value was obtained using a χ2 test.
P<0.05 is considered to indicate a statistically significant difference (two-sided). HR, hazard ratio; CI, confidence interval; RSF1, remodeling and spacing factor 1; TNM, tumor node metastasis.